Verition Fund Management’s Meridian Bioscience Inc VIVO Stock Holding History

Verition Fund Management’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-7,169	Closed	-$238K	–	2767
2022 Q4	$238K	Sell	7,169 -34,440	-83%	-$1.11M	﹤0.01%	1635
2022 Q3	$1.31M	Buy	+41,609	New	+$1.35M	0.01%	1198
2015 Q1	–	Sell	-29,273	Closed	-$482K	–	532
2014 Q4	$482K	Buy	29,273 +16,172	+123%	+$277K	0.11%	89
2014 Q3	$232K	Buy	+13,101	New	+$257K	0.03%	504

Other funds holding VIVO

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Verition Fund Management's VIVO Position: Q1 2023 in Review

Verition Fund Management sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 7,169 shares — an estimated $238K sold.

Verition Fund Management first reported a position in VIVO in Q3 2014 and held it in 4 quarters. The position peaked at $1.31M in Q3 2022. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

Verition Fund Management reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
Verition Fund Management sold 7,169 Meridian Bioscience Inc shares in Q1 2023, an estimated $238K.
Verition Fund Management first reported a position in Meridian Bioscience Inc in Q3 2014 and held it in 4 quarters.
Verition Fund Management's Meridian Bioscience Inc position peaked at $1.31M in Q3 2022.
2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on Verition Fund Management's 13F filing for Q1 2023, filed 15 May 2023.